Age-related macular degeneration
The progressive damage to the retina seen in the most common advanced form of age-related macular degeneration (AMD) cannot currently be slowed, let alone stopped. Researchers are pursuing a wide variety of strategies to change this.
-
Produced with support from:
This Nature Outline is editorially independent, produced with financial support from a third party. About this content.
Nature is pleased to acknowledge the financial support of Alexion in producing this Outline. The sponsor retains the sole responsibility for the following message.
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
